Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AUROBINDO PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AUROBINDO PHARMA CIPLA/
AUROBINDO PHARMA
 
P/E (TTM) x 36.3 18.2 199.1% View Chart
P/BV x 4.2 3.9 106.8% View Chart
Dividend Yield % 0.5 0.3 181.9%  

Financials

 CIPLA   AUROBINDO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
AUROBINDO PHARMA
Mar-19
CIPLA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs586830 70.5%   
Low Rs357527 67.7%   
Sales per share (Unadj.) Rs207.0333.9 62.0%  
Earnings per share (Unadj.) Rs18.640.4 46.1%  
Cash flow per share (Unadj.) Rs33.251.8 64.1%  
Dividends per share (Unadj.) Rs4.002.50 160.0%  
Dividend yield (eoy) %0.80.4 230.4%  
Book value per share (Unadj.) Rs195.5237.1 82.5%  
Shares outstanding (eoy) m806.35585.91 137.6%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.32.0 112.0%   
Avg P/E ratio x25.316.8 150.7%  
P/CF ratio (eoy) x14.213.1 108.4%  
Price / Book Value ratio x2.42.9 84.2%  
Dividend payout %21.56.2 347.2%   
Avg Mkt Cap Rs m379,912397,569 95.6%   
No. of employees `00025.817.9 144.7%   
Total wages/salary Rs m30,27025,849 117.1%   
Avg. sales/employee Rs Th6,459.610,956.9 59.0%   
Avg. wages/employee Rs Th1,171.21,447.7 80.9%   
Avg. net profit/employee Rs Th580.21,324.3 43.8%   
INCOME DATA
Net Sales Rs m166,949195,636 85.3%  
Other income Rs m3,4421,553 221.6%   
Total revenues Rs m170,391197,189 86.4%   
Gross profit Rs m32,06039,519 81.1%  
Depreciation Rs m11,7476,680 175.9%   
Interest Rs m1,9742,626 75.2%   
Profit before tax Rs m21,78231,767 68.6%   
Minority Interest Rs m-47527 -1,757.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m6,3127,269 86.8%   
Profit after tax Rs m14,99523,645 63.4%  
Gross profit margin %19.220.2 95.1%  
Effective tax rate %29.022.9 126.7%   
Net profit margin %9.012.1 74.3%  
BALANCE SHEET DATA
Current assets Rs m117,038153,645 76.2%   
Current liabilities Rs m43,931120,429 36.5%   
Net working cap to sales %43.817.0 257.9%  
Current ratio x2.71.3 208.8%  
Inventory Days Days96135 70.8%  
Debtors Days Days8564 133.6%  
Net fixed assets Rs m107,424103,909 103.4%   
Share capital Rs m1,613586 275.2%   
"Free" reserves Rs m156,018138,322 112.8%   
Net worth Rs m157,630138,908 113.5%   
Long term debt Rs m23,6931,800 1,316.6%   
Total assets Rs m236,626264,544 89.4%  
Interest coverage x12.013.1 91.9%   
Debt to equity ratio x0.20 1,160.3%  
Sales to assets ratio x0.70.7 95.4%   
Return on assets %7.29.9 72.2%  
Return on equity %9.517.0 55.9%  
Return on capital %12.823.8 53.9%  
Exports to sales %33.049.6 66.6%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs m55,17597,091 56.8%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m56,03697,316 57.6%   
Fx outflow Rs m6,76440,589 16.7%   
Net fx Rs m49,27256,727 86.9%   
CASH FLOW
From Operations Rs m30,68516,220 189.2%  
From Investments Rs m1,040-28,768 -3.6%  
From Financial Activity Rs m-29,48819,191 -153.7%  
Net Cashflow Rs m2,3406,656 35.2%  

Share Holding

Indian Promoters % 16.0 54.1 29.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.0 153.5%  
FIIs % 23.7 27.7 85.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.2 256.9%  
Shareholders   161,166 69,601 231.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 15, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS